

Product Data Sheet

Product Name: MW-150
Cat. No.: GC65297

Chemical Properties

Cas. No. 1628502-91-9

Formula C₂₄H₂₃N₅ M.Wt 381.47

Solubility DMSO : 40 mg/mL (104.86 mM;
Need ultrasonic) Storage Store at -20°C

General tips For obtaining a higher solubility , please warm the tube at 37 °C and shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.

Shipping Condition Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request.


Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

Product Data Sheet

Structure



Background

MW150 (MW01-18-150SRM) is a selective, CNS penetrant, and orally active inhibitor of p38 α MAPK with a K_i of 101 nM. MW-150 inhibits the ability of the endogenous p38 α MAPK to phosphorylate an endogenous substrate MK2 in activated glia[1].

MW-150 inhibits in a concentration-dependent manner the ability of the endogenous p38 α MAPK to phosphorylate an endogenous substrate MK2 in activated glia[1]. MW-150 blocks in a concentration-dependent manner the increased IL-1 β production by activated glia. The IC₅₀ values are 332 nM and 936 nM for MK2 and IL-1 β , respectively[1].

MW-150 (2.5 mg/kg; oral daily for 3-4 months) improves the APP/PS1 transgenic (Tg) mice performance in radial arm water maze (RAWM) and contextual fear conditioning tests[1]. MW-150 (2.5 mg/kg; given i.p.; daily for 14 days) treatment in APPNLh/NLh $\times$ PSP264L/P264L knock-in mouse

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

Product Data Sheet

(with no overexpression of the amyloid precursor protein) exhibits RAWM behavior indistinguishable from WT mice[1].

[1]. Roy SM, et al. Targeting human central nervous system protein kinases: An isoform selective p38 α MAPK inhibitor that attenuates disease progression in Alzheimer's disease mouse models. ACS Chem Neurosci. 2015 Apr 15;6(4):666-80.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA